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Abstract  
Introduction. Atrial fibrillation (AF), the most common and rising disorder of cardiac rhythm, is 
quite difficult to control and/or to treat. Non pharmacological therapies for AF may involve the 
use of dedicated pacing algorithms to detect and prevent atrial arrhythmia that could be a trigger 
for AF onset. Selection 900E/AF2.0 Vitatron DDDRP pacemaker (1) keeps an atrial arrhythmia 
diary thus providing detailed onset reports of arrhythmias of interest, (2) provides us data about 
the number of premature atrial contractions (PACs) and (3) plots heart rate in the 5 minutes 
preceding the detection of an atrial arrhythmia. Moreover, this device applies four dedicated 
pacing therapies to reduce the incidence of atrial arrhythmia and AF events.
Aim of  the  Study.  To analyze  the reliability to  record  atrial  arrhythmias  and evaluate 
effectiveness of its AF preventive pacing therapies.
Material and Methods. We enrolled 15 patients (9 males and 6 females, mean age of 71±5 
years, NYHA class I–II), with a DDDRP pacemaker implanted for a “bradycardia–tachycardia” 
syndrome, with advanced atrioventricular conduction disturbances. We compared the number 
and duration of AF episodes’ stored in the device with a contemporaneous 24h Holter 
monitoring. After that, we switched on the atrial arrhythmias detecting algorithms, starting from 
an atrial rate over 180 beats per minute for at least 6 ventricular cycles, and ending with at least 
10 ventricular cycles in sinus rhythm. Thereafter, in order to evaluate the possible reduction in 
PACs number and in number and duration of AF episodes, we tailored all the four pacing 
preventive algorithms. Patients were followed for 24±8 months (from 20 to 32 months).
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Results. All 59 atrial arrhythmia episodes occurred in the first part of this trial, were correctly 
recorded by both systems, with a correlation coefficient (r) of 0.96. During the follow–up, we 
observed a significant reduction not only in PACs number (from 83±12/day to 2.3±0.8/day) but 
also in AF episodes (from 46±7/day to 0.12±0.03/day) and AF burden (from 93%±6% to 
0.3%±0.06%). An increase in atrial pacing percentages (from 3%±0.5% to 97%±3%) was also 
contemporaneously observed.
Conclusion. In this pacemaker, detection of atrial arrhythmia episodes is highly reliable, thus 
making   available   an   appropriate   monitoring   of   heart   rhythm,   mainly   suitable   in   AF 
asymptomatic  patients.   Moreover,  the  significant  reduction  of  atrial  arrhythmia  episodes 
indicates that this might represent a suitable therapeutic option for an effective preventive 
therapy of AF in paced brady–tachy patients.
Key Words: Sick Sinus Syndrome, Atrial Fibrillation, Atrial Pacing, Pacing Algorithms, Non-
Pharmacological Therapy
Introduction
               Atrial fibrillation (AF) represents one of the major clinical, social and economical 
medical challenge1,2. Progressive ageing is associated with an inevitable rising in incidence and 
prevalence of this rhythm disorder3,4, which causes not only impairments in functional capability 
being associated to a greater incidence of cerebro-vascular events, but also a rising request for 
emergency room visits and hospital admission, mainly in patients affected by left ventricular 
dysfunction or by other significant cardiovascular diseases.
               Different therapeutic strategies, both pharmacological and non pharmacological, are 
available to restore sinus rhythm, prevent arrhythmia recurrences and cardio–embolic events and 
control the mean ventricular rate1,2,5. What is still a challenge is how to tailor appropriate 
strategy and therapy for each patient.
            It is an affirming concept that AF should not be considered as a simple cardiac rhythm 
disturbance, but rather as a syndrome with a variety of clinical presentations and two frequently 
negative hemodynamic feature: (1) the lack of atrial contribution to ventricular filling and (2) the 
irregularity and/or the fast shortening of cardiac cycle lenght1,2,5,6. The abnormal automaticity of 
pulmonary veins’ foci7  represents a critical determinant for AF onset. It’s well known, 
nowadays, that a (1) critical atrial mass is necessary to maintain the re-entry atrial circuits8 and 
that (2) the adrenergic activation determines a pro-arrhythmic effect on bursts originating from 
the pulmonary veins[9] or on arrhythmia recurrence after a cardioversion10. Notwithstanding, it’s 
almost impossible to figure out a temporal prevision of the evolution of this “AF syndrome” in 
each patient.
            In 1995, Wijffels and coll.11 showed, for the first time, that AF causes several changes in 
atrial electrophysiological properties that could be responsible for the clinical progression and 
maintenance of this tachyarrhythmia. The persistence of electrical disorders was found to be 
proportional to the duration of atrial high–rate pacing8,11.
            There are three main electrophysiological assumptions12–14 for pacing prevention of AF 
widely accepted:
1. to reduce the arrhythmogenetic effects of bradycardia and, in particular, the atrial 
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refractory periods dispersion;
2. to override atrial premature contractions (PACs), as a possible cause of AF onset;
3.  to  reduce  the  compensatory   pauses  after   an  atrial  or   a  ventricular   premature 
contraction, thus reducing the dispersion of atrial refractoriness induced by the “short 
cycle – long cycle” mechanism.
            A prospective randomised study from Andersen and coll.15 on 225 patients with sick 
sinus syndrome, showed that atrial pacing (AAI) not only significantly reduced the incidence and 
burden of AF and thromboembolisms when compared with ventricular one, but also that there 
was a significant reduction in total and cardiovascular mortality.
            To improve the capability to prevent the onset of AF, other several approaches have been 
tested. In patients with marked intraatrial conduction period delays, Saksena16 and Daubert17 
suggested to resynchronize both atria with dual–site atrial pacing, in different stimulation sites, 
in order to reduce the consequent atrial electrical abnormalities. Nowadays, this approach has 
been less considered, because of a low efficacy on AF incidence and burden, with frequent 
episodes of cross–talk and interference due to the dipole wide range, and because of the higher 
threshold needed for left atrial pacing. As alternative solutions, Padeletti and coll.18 suggested 
the use of a single atrial lead on atrial septum. Several studies are still ongoing, with contrasting 
preliminary results.
            It’s also well known that variability in the origin of PACs should increase the probability 
of a re-entry mechanism, mainly in presence of an anomalous substrate. On this account, it has 
been proposed to reduce atrial rate variability using an overdrive atrial steady stimulation alone, 
although this approach did not obtain significant results. Alternatively, other pacing techniques 
such as bursts and drives algorithms have been proposed. Several trials19–24 have been done to 
evaluate   the   safety   and   efficacy   of   these   devices   in   terminating   spontaneous   atrial 
tachyarrhythmias, but the results were quite disomogeneous and so this approach is far from 
being definitively accepted.
               In particular, the Atrial Dynamic Overdrive Pacing Trial (ADOPT)25  evaluated the 
effects of atrial overdrive pacing algorithms in 319 patients (mean age 71±10 years) with 
paroxysmal atrial fibrillation (3-3.5 documented atrial fibrillation episodes in the 12 weeks prior 
to implant). Atrial pacing reduced symptomatic atrial fibrillation burden (On: 1.9% vs. Off: 
2.5%).   Symptomatic   atrial   fibrillation  burden  decreased  over   time  for   both  groups.   No 
significant difference was noted in the number of atrial fibrillation episodes (On: 3.2 ± 8.6 vs. 
Off: 4.3 ± 11.5) or total hospitalizations (On: 9% vs. Off: 13%) between the two groups. Quality-
of- life improved in both groups.
            Moreover, in the ATTEST study26 was evaluated the effectiveness of an atrial therapy 
device utilizing preventative and antitacycardia pacing in patients with symptomatic atrial 
fibrillation. The implanted device was an AT500 (Medtronic Inc, Minneapolis, MN) DDDR 
pacemaker, with a mode switching algorithm (DDIR) during atrial tachyarrhythmias. Atrial 
antitachycardia pacing was available in rate adaptive burst or ramp modes, and the device also 
could employ 3 preventative atrial pacing algorithms to attempt to prevent AF/AT recurrences. 
After a one-month run in period, patients were randomized to either atrial prevention or 
termination on or off, and followed for three months. At the end of the trial, there was observed 
no significant difference between the two groups in the run in period or in follow up in either 
frequency, burden or symptomatic frequency of AT/AF. The efficacy of device ATP was 54% in 
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converting atrial arrhythmias to sinus rhythm as evaluated by the device and the accuracy of the 
detection algorithm was 99.9%.
            Based on the hypothesis of the effectiveness of a non–pharmacological antiarrhythmic 
electrical therapy, our study was aimed at evaluate the reliability of the four specific pacing 
algorithms of the DDDRP pacemaker, the Selection® 900E/AF2.0 Vitatron™, and to reduce the 
trigger mechanisms, possibly responsible for AF onset.
Materials and Methods
                    We initially evaluated the atrial arrhythmia recording reliability in 15 patients, 
implanted with a Selection™ 900E/AF2.0 Vitatron® device, for a “brady–tachy” syndrome, 
with advanced atrioventricular conduction disturbances. Patients were enrolled in a period of 10 
months, starting from January 2000 and ending in October 2000. Patients were 9 males and 6 
females, with a mean age of 71±5 years, without any previous history of myocardial infarction, 
angina, diabetes and other known risk factors and in I NYHA functional Class. All patients were 
initially under oral anticoagulant therapy (INR 2.0–3.0) and IC antiarrhythmic drug therapy 
(Acetate Flecainide 200 mg per day) for at least 6 months prior to implant. Therapies were not 
discontinued during the follow–up.
            In order to evaluate the Selection™ 900E/AF2.0 Vitatron® atrial arrhythmia recording 
reliability,  we  compared  the  number   of   atrial  arrhythmic  episodes   and  their   onset  and 
duration,properly stored in the pacemaker, with a contemporaneous 24h standard Holter cassette 
recording (Ela Medical™ Synetec® System, version 1.20). A statistical correlation analysis was 
performed. The pacemaker parameters were settled in order to record atrial arrhythmic episodes 
lasting at least 6 ventricular cycles for their onset and 10 ventricular cycle for their ending. The 
atrial cut–off detection rate was of 180 atrial waves per minute. Clinical and follow–up features 
of our population are summarized in Table 1. Data are expressed as mean ± SEM. Paired t–
Student test was performed.
            The second aim was a middle–term efficacy evaluation (mean follow up 24±8 months, 
i.e. from 20 to 32 months) of all the four Selection™ 900E/AF2.0 Vitatron® available pacing 
algorithms, in order to prevent the trigger mechanisms, possibly responsible for AF onset. Each 
pacing algorithm was tailored according to the clinical and electrophysiological features of each 
patient, according to the previously recorded atrial arrhythmic events.
            The four used atrial pacing algorithms were the following four:
1. Pace Conditioning™: this algorithm consist on a permanent overdrive atrial pacing with an 
atrial pacing rate of about 15 b.p.m. higher than the beneath intrinsic effective atrial rate.
2.   PAC   Suppression™:  this   algorithm   is   designed   to   reduce   the   incidence   of   atrial 
tachyarrhythmia by a temporary stable atrial overdrive pacing following a PAC. This algorithm 
provides a temporary atrial overdrive pacing lasting for 600 ventricular cycles after a sensed 
PAC. At the end of this 600 ventricular cycles, the pacing rate progressively reduces till the 
lower   rate   limit   or   till   the   emergence   of   a   stable   sinus   rhythm.
3. Post–PAC Response™: this algorithm is designed to reduce the post–extrasystolic pauses by 
controlling the atrial rate in the 2 beats after a PAC. The first atrial paced beat’s rate is 
determined by an averaging between the previous physiologic RR interval and the PAC pairing 
rate. From the second beat onwards, the atrial fleeing rate returns to the atrial physiologic rate.
4. Post–Exercise Rate Control™: the post–exercise rate control has been specifically designed 
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to prevent a too fast lowering of heart rate after a physical activity. The post–exercise rate 
increases proportionally to the difference between the physiological heart rate and the target 
heart rate, i.e. 90% of the physiological heart rate.
Table 1 – Patients baseline caracteristics and follow-up
Results
            During the first part of this trial, i.e. that comparing Holter recordings and pacemaker 
storage data, we observed 59 episodes of paroxysmal AF, lasting from some seconds to some 
minutes, with a highly significant correlation coefficient between Holter and pacemaker 
recordings (r=0.96) (Fig. 1). The AF mean duration was of 70,9±46,8 s. in the Holter group and 
of 69,6±47,4 in pacemaker recordings (p = 0.881; 95% confidence interval: –18.48 to 15.88). 
Differences between timing and duration of the two recordings is likely to be due to the cassette 
tracking speed features.
            As shown in Fig. 2, during the second half of our trial, the antiarrhythmic algorithms 
produced a significant and progressive reduction in AF episodes (from 46±7 episodes/day to 
0,12±0,03 episodes/day; p<0.001; 95% confidence interval: 41.69 to 50.07) and in AF burden 
(from 93%±6% to 0,3%±0,06%; p<0.001; 95% confidence interval: 89.53 to 95.87), with a 
concomitant increase in atrial pacing percentage (from 3%±0.5% to 97%±3%; p<0.001; 95% 
confidence interval: –95.61 to –92.39). AF burden was evaluated and measured during the 
follow up period using the pacemaker storage data, and no comparison were made with AF 
burden prior to implant, because of the lack of a real value of this data in our patients, that were 
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sometimes asymptomatic ones. We observed also a decrease in premature atrial contractions 
from 83±12 PACs/day to 2,3±0,8 (p<0.001; 95% confidence interval: –87.06 to –74.34) (Fig. 2). 
The same method was used to record APCs in the pre- and post- implant period, i.e. the Holter 
monitoring, and also during all the follow up period, i.e. a retrospective analysis of pacemaker 
data storage.
Fig. 1 - Concordance Between Holter and Pacemaker Recordings
Fig. 2 - Supraventricular Tachyarrhythmia Reduction After Switching on the 4 Pacing 
Preventive Therapies
            However, it was unfeasible to perform a reliable multivariate analysis because of the 
reduced number of patients, because of the lack of multiple risk factors, because of the 
contemporaneous usage in the same patients of acetate flecainide and of pacing prevention 
algorithms.
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Discussion and Conclusion
               Presently, very few clinical randomised trials29–32  have compared the overlapping 
between pacemaker stored data and Holter monitoring ones, so that there is not a significant 
evidence of data about the reliability of these devices in properly recognising and monitoring 
supraventricular tachyarrhythmias. It’s also well known that bipolar leads often are not enough 
able to discriminate ventricular far field from normal P-wave amplitude or from wavelets of AF. 
An Atrial Blanking feature, long enough, may completely mask this phenomenon, but it also 
represents a blind interval for the atrial channel, sometimes subsequently resulting in a possible 
negative effect for an optimal arrhythmia detection. Recently, Nicotra33 carried out a method for 
atria l sensing and blanking programming in order of guarantee reliable diagnostics in patients 
with paroxysmal AF. They proposed a decisional flow-chart based on the scanning of ventricular 
far field timing and amplitude that could focus and quantify this phenomenon for every kind of 
implanted device (Fig. 3). This approach was also used in the present study during the follow–
up. 
Fig. 3 - Decisional Flow-Chart
               Our data confirm the significant reliability of Selection™ 900E/AF2.0 Vitatron® 
algorithms for detecting and monitoring AF. Moreover, we recorded a significant number of 
supraventricular tachyarrhythmia’s episodes, thus making stronger the statistical reliability of 
these data. Subsequently, we detected a progressive and significant reduction in AF burden and 
episodes. This decreasing in AF episodes and burden may be mainly related to the increase of 
atrial pacing, obtained by using a newly designed pacing overdrive algorithm responsible of 
atrial ectopic beats’ suppression in keeping with several trials11–28.
            Most of the discussed trials showed a lower reduction in AF episodes and burden if 
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compared with our study (AF burden decreasing from 85% to 35% vs. a reduction from 93% to 
0.3%; p<0.001; 95% confidence interval: –9.253 to –6.747). As showed in our recordings, the 
exceeding share of AF episodes and AF burden reduction is more likely to be entrusted to the 
newly designed four preventive pacing algorithms stored in the tested device (Selection® 
900E/AF2.0® Vitatron™ pacemaker). Alternatively, as the data shown in fig. 2 seems to 
underline, i.e. that the efficacy of pacing for reducing AF episodes/day was evident after only six 
months of treatment, may suggest that also atrial remodelling could play a role. Electrical, 
mechanical and anatomical remodelling indicate structural alterations that, once established, may 
vanish any attempt to restore sinus rhythm. Atrial fibrosis is probably the most critical factor of 
the remodelling process and appears to be largely media ted by several mechanisms. Our clinical 
data indicate that these non pharmacological interventions may reduce, in a roundabout way, AF 
burden and episodes, probably interfering also with someone of those electrical and structural 
remodelling processes. It is possible, however, that having a very few patients, although 
followed for a median time of 24 months, we have overestimated the general possible reduction 
in AF episodes and burden because of a strong selection of our patients. In particular, we 
selected our patients on the basis of their atrial tachyarrhythmias’ onset mechanisms, and we 
tailored the available preventive pacing algorithms in each patient on the basis of each onset. 
This tailoring of pacing preventive algorithms on the basis of the different onsets in each patient, 
associated with the well known anti–remodelling effect of atrial overdrive pacing on atrial 
refractoriness dispersion, was the more important goal of our study and the likely reason of the 
observed marked reduction in AF episodes and burden. Therefore, these examined pacing 
algorithms may represent an effective therapeutical options to contrast the nearly inevitable 
progression of this arrhythmia towards its permanent form.
            The AF antiarrhythmic drugs therapy represents the first and more effective therapy, 
although it is well known that it is not always effective and free from side effects. In our patients, 
implanted for a sick sinus syndrome and at least partially resistant to AF pharmacological 
treatment, new interventional non–pharmacological solutions, such as tailored antiarrhythmic 
pacing algorithms, may represent a further effective therapeutical option. Recent analysis of 
AFFIRM33 and RACE trial34 showed that, in patients older than 65 years, with well defined risk 
factors, a therapeutical strategy based on ventricular rate control is not inferior to a strategy of 
maintaining sinus rhythm (rhythm control). However, this issue is still debated. Indeed, other 
clinical trials and sub–analysis35–40 showed that sinus rhythm restoration has to be preferred 
compared to rhythm control.
            In conclusion, our experience suggests the reliability of well tailored pacing algorithms 
on AF control in selected patients with brady-tachy syndrome, refractory to pharmacological 
rhythm control. However, we should say that this study is partially limited by the small and 
highly selected sample used, that reduces the possibility of translating theses results to general 
population. Moreover, this was not a truly randomized, controlled study, and so interpretation of 
the clinical significance of the reduction of AF episodes, as also shown however by several other 
trials in International Literature, is uncertain, thus not allowing us for making really definitive 
conclusions. The main information, however, we can derive from this trial is that we should 
better evaluate, before every pacemaker implantation, the different AF onsets of each patient 
eligible for such a procedure, because only a really profound knowledge of the different onset 
mechanisms of atrial tachyarrhythmias in each subject may give us the possibility of choosing a 
really effective implantable device for these sometimes very different patients, thus obtaining the 
maximum effective clinical results from these pacing algorithms in terms of reduction of AF 
episodes and burden.
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